Impact of MCA stenosis on the early outcome in acute ischemic stroke patients

PLoS One. 2017 Apr 7;12(4):e0175434. doi: 10.1371/journal.pone.0175434. eCollection 2017.

Abstract

Background: Asians have higher frequency of intracranial arterial stenosis. The present study aimed to compare the clinical features and outcomes of ischemic stroke patients with and without middle cerebral artery (MCA) stenosis, assessed by transcranial sonography (TCS), based on the Taiwan Stroke Registry (TSR).

Methods: Patients with acute ischemic stroke or transient ischemic attack registered in the TSR, and received both carotid duplex and TCS assessment were categorized into those with stenosis (≥50%) and without (<50%) in the extracranial internal carotid artery (ICA) and MCA, respectively. Logistic regression analysis, Kaplan-Meier method and Cox proportional hazard model were applied to assess relevant variables between groups.

Results: Of 6003 patients, 23.3% had MCA stenosis, 10.1% ICA stenosis, and 3.9% both MCA and ICA stenosis. Patients with MCA stenosis had greater initial NIHSS, higher likelihood of stroke-in-evolution, and more severe disability than those without (all p<0.001). Patients with MCA stenosis had higher prevalence of hypertension, diabetes and hypercholesterolemia. Patients with combined MCA and extracranial ICA stenosis had even higher NIHSS, worse functional outcome, higher risk of stroke recurrence or death (hazard ratio, 2.204; 95% confidence intervals, 1.440-3.374; p<0.001) at 3 months after stroke than those without MCA stenosis.

Conclusions: In conclusion, MCA stenosis was more prevalent than extracranial ICA stenosis in ischemic stroke patients in Taiwan. Patients with MCA stenosis, especially combined extracranial ICA stenosis, had more severe neurological deficit and worse outcome.

MeSH terms

  • Aged
  • Constriction, Pathologic / pathology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Middle Cerebral Artery / pathology*
  • Stroke / pathology
  • Stroke / physiopathology*

Grants and funding

This project was funded by the Bureau of Health Promotion, Department of Health Taiwan Stroke Registry grant (DOH-95~98-HP-1102); Department of Health Clinical Trial and Research Center of Excellence (DOH100-TD-B-111-004), Center of Excellence for Clinical Trial and Research in Neuroscience (DOH102-TD-B-111-003), Taiwan; the Ministry of Health and Welfare (MOHW105-TDU-B-212-133018), Taiwan; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002), China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project (BM104010092), NRPB Stroke Clinical Trial Consortium (MOST 103-2325-B-039 -006); Taiwan Ministry of Science and Technology (MOST 105-2314-B-341-004); Shin Kong Wu Ho-Su Memorial Hospital (SKH-8302-103-DR-17); Dr. Chi-Chin Huang Stroke Research Center, Taipei, Taiwan; Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.